Treating cardiac allograft rejection: present approach--analysis of 100 consecutive patients

J Heart Transplant. 1990 May-Jun;9(3 Pt 2):288-91.

Abstract

In addition to rejection, complications of rejection prophylaxis and treatment are major causes of mortality and morbidity during the first year after heart transplantation. To decrease complications related to antirejection treatment, our present approach is to assess each rejection episode individually and to adjust treatment accordingly. This article presents the analysis of rejection in the last 100 patients who underwent heart transplantation at our institution.

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Graft Rejection / drug effects*
  • Heart Transplantation*
  • Humans
  • Immunosuppression Therapy
  • Immunosuppressive Agents / therapeutic use*
  • Methylprednisolone / therapeutic use
  • Middle Aged
  • Muromonab-CD3
  • Prednisone / therapeutic use

Substances

  • Antibodies, Monoclonal
  • Immunosuppressive Agents
  • Muromonab-CD3
  • Prednisone
  • Methylprednisolone